A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

2025-524693-42-00 Protocol BP46355 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 9 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol BP46355

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 196
Countries 1
Sites 1

Stable Coronary Artery Disease (CAD)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
9 Mar 2026 → ongoing
Decision date (initial)
2026-03-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Stable Coronary Artery Disease (CAD)

VersionLevelCodeTermSystem organ class
20.0 PT 10011078 Coronary artery disease 100000004849
26.0 LLT 10088820 Clinical trial healthy volunteer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 196 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-03-09 2026-03-10

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-19 Netherlands Acceptable with conditions
2026-03-06
2026-03-06
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-29 Netherlands Acceptable with conditions
2026-03-06
2026-04-29